Type 2 Diabetes Trial, Recruiting NCT07187479 Sponsor: Well Cell Global Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT07187479
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any gender
  • People who have been diagnosed with moderate-to-severe chronic kidney disease (CKD stage 3b, 4, or 5) and type 2 diabetes for at least 6 months before the screening appointment
  • People whose diabetes may be managed with tablets, injections (including insulin or GLP-1 medications), or a combination of these
  • People whose treatment plan for any related health conditions has been stable for at least the past 6 months, in the opinion of the study doctor
  • People who the study doctor believes are able to give informed consent, follow study instructions, and attend all required visits
  • Women who are not able to become pregnant — either because they are aged 50 or older and have been through menopause for at least one year, or because they have had a surgical procedure such as tubal ligation, removal of the ovaries, or a hysterectomy
  • Women who could become pregnant, provided they have a negative pregnancy blood test at screening and agree to use an accepted form of contraception from screening until at least 30 days after the last study treatment

Who may not be able to join:

  • People who have received treatment for cancer within the past 2 years
  • People who are currently pregnant or plan to become pregnant during the study
  • People who have used non-prescription opioids or recreational/psychoactive drugs within the past year
  • People who have had a severe low blood sugar episode requiring emergency care or treatment (such as glucagon or an intravenous glucose drip) within the past 6 months, unless the study's medical monitor has specifically approved their enrolment
  • People who have taken part in another clinical study involving an experimental drug, procedure, or an investigation into blood sugar control methods within the past month
  • People who are currently breastfeeding or plan to breastfeed during the study
  • People who test positive at screening for HIV, hepatitis B, or hepatitis C
  • People whose blood test results at screening show certain abnormal levels — including low red blood cells, low white blood cells, low platelets, or elevated liver-related markers — beyond the thresholds set by the trial (confirm specific values with trial site)
  • People who, in the study doctor's opinion, have psychiatric, behavioural, thinking, or other clinical difficulties that could affect their safety or ability to follow the study requirements
  • People who are currently receiving dialysis at the time of screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sungchun Lee, MD, Arizona Kidney Disease and Hypertension Centers

Phone: 205-612-4763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Well Cell Global
Registry
ClinicalTrials.gov
Start date
14 October 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Estimated Glomular Filtration Rate (eGFR); Blood Urea Nitrogen/Creatinine Ratio (BUN/Cr); Cystatin C; Urine albumin-creatinine ratio (ACR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov